Skip to content

A nested case-control study for the effect prediction model of neoadjuvant chemotherapy for muscle invasive bladder cancer based on molecular markers and image omics

A nested case-control study for the effect prediction model of neoadjuvant chemotherapy for muscle invasive bladder cancer based on molecular markers and image omics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047632
Enrollment
Unknown
Registered
2021-06-21
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder carcinoma

Interventions

Case group:Nil

Sponsors

Xiangya Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patients with muscle invasive bladder cancer diagnosed by pathology department of our hospital; 2. Clinical stage t2-t4an0 / xm0; 3. Clinicians evaluate the patients suitable for radical cystectomy; 4. Karnofsky score >=70; 5. Patients over 18 years old; 6. Laboratory indexes: absolute neutrophil count (ANC) >=1000/mm3, platelet count >=100000/mm3, hemoglobin >=9.0g/dl, bilirubin =60mL/min/1.73m2.

Exclusion criteria

Exclusion criteria: 1. Patients who have previously received radiotherapy, immunotherapy and other adjuvant treatment of tumor; 2. Patients with serious heart disease (i.e. grade III and above heart function); 3. Patients with serious medical or mental diseases, including severe active infection; 4. Patients who received other surgical treatment 4 weeks ago; 5. The following symptoms occurred within 6 months: myocardial infarction, severe/unstable angina, coronary artery / peripheral artery bypass, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack; 6. Patients with sustained arrhythmia >=2 (NCI CTCAE version 4.0 grade)(The attachment 2); 7. Patients with diseases or infections related to human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); 8. Patients who participated in other clinical trials at the same time; 9. Pregnant or lactating women; 10. Patients with alcohol or narcotic drug abuse, drug use history, or mental history (such as schizophrenia, obsessive-compulsive disorder, depression), who have antagonistic personalities, bad motivation, paranoia, or other emotional or intellectual problems that may affect the informed effectiveness of the study; 11. Patients who are unable to cooperate with the relevant examination of the project and do not agree to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Pathological stage;Abdominal computed tomography;

Countries

China

Contacts

Public ContactZu Xiongbing

Xiangya Hospital

zuxbxyyy@126.com+86 13787157190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026